Subcutaneous Pembro vs IV in NSCLC

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.
Medscape Medical News

source https://www.medscape.com/viewarticle/subcutaneous-pembro-par-iv-administration-lung-cancer-2025a10007lc?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost